Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2019 16:15 ET | Source: Aravive, Inc.

Aravive Announces Executive Management Transition Plan

HOUSTON, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening...
August 08, 2019 08:00 ET | Source: Aravive, Inc.

Aravive Announces Participation at Wedbush PacGrow Healthcare Conference

HOUSTON, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening...
August 07, 2019 16:05 ET | Source: Aravive, Inc.

Aravive Reports Second Quarter 2019 Financial Results and Provides Recent Corporate Updates

HOUSTON, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening...
July 31, 2019 07:05 ET | Source: Aravive, Inc.

Aravive Reports Preliminary Results of AVB-500 from the First Cohort of the Phase 1b/Phase 2 Recurrent Platinum Resistant Ovarian Cancer Trial

AVB-500 in combination with standard of care demonstrates early proof of concept for anti-tumor activity in platinum-resistant ovarian cancer Aravive to expand enrollment in Phase 1b Trial of...
July 08, 2019 07:05 ET | Source: Aravive, Inc.

Aravive Announces Independent Data Monitoring Committee Recommends Continuation of Phase Ib Study of AVB-500 In Recurrent Platinum Resistant Ovarian Cancer After Review of First Two Cohorts of Patients

HOUSTON, July 08, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Aravive) (NASDAQ:ARAV), a clinical-stage biopharmaceutical company, announced that the independent Data Monitoring Committtee (DMC) has...
May 08, 2019 16:05 ET | Source: Aravive, Inc.

Aravive Reports First Quarter 2019 Financial Results and Provides Recent Corporate Updates

HOUSTON, May 08, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening...
March 19, 2019 07:05 ET | Source: Aravive, Inc.

Aravive Announces Retrospective Analysis Showing Increased GAS6 Levels Associated with Chemoresistance and Decreased Progression Free Survival in Ovarian Cancer

HOUSTON, March 19, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that data from a non-clinical ovarian cancer study of AVB-500 and the...
March 08, 2019 16:05 ET | Source: Aravive, Inc.

CORRECTING AND REPLACING - Aravive Announces Participation at Cowen and Company 39th Annual Health Care Conference

HOUSTON, March 08, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that company management will participate at the following upcoming...
March 07, 2019 16:04 ET | Source: Aravive, Inc.

Aravive Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Recent Corporate Updates

HOUSTON, March 07, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company focused on developing innovative therapies that target important survival...
March 05, 2019 16:05 ET | Source: Aravive, Inc.

Aravive Announces Participation at Cowen and Company 39th Annual Health Care Conference

HOUSTON, March 05, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that company management will participate at the following upcoming...